Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer

Background TAS-102 is a nucleoside antitumor agent consisting of trifluridine (FTD) and tipiracil hydrochloride (TPI). We investigated the recommended dose (RD) of TAS-102 plus irinotecan for metastatic colorectal cancer refractory to 5-fluorouracil (5-FU) and oxaliplatin. Methods This study was use...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Invest New Drugs
Hlavní autoři: Doi, Toshihiko, Yoshino, Takayuki, Fuse, Nozomu, Boku, Narikazu, Yamazaki, Kentaro, Koizumi, Wasaburo, Shimada, Ken, Takinishi, Yasutaka, Ohtsu, Atsushi
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer US 2015
Témata:
Phase I Studies
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4768213/
https://ncbi.nlm.nih.gov/pubmed/26163340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0271-1
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky